短程术前放疗后MRI模拟引导加量治疗不可切除直肠癌的安全性(SUNRISE):一项随机II期试验的中期分析
SUNRISE试验中期分析纳入43例经盆腔MRI评估为cT3-4或区域淋巴结阳性伴直肠系膜筋膜阳性或T4b的不可切除直肠癌患者,随机分为SCPRT加量组(25 Gy/5次+肿瘤区4 Gy后4周期化疗)与术前放化疗组(50 Gy/25次同步化疗)。实验组≥3级毒性10/21(47.6%)vs 对照组4/21(19.0%),R0切除率意向性分析为65.1%。结论认为MRI模拟引导加量毒性可接受,试验按计划继续。
要点
- 实验组术前治疗期间≥3级毒性为10/21(47.6%),对照组为4/21(19.0%)。
- 实验组17例(81.0%)与对照组13例(61.9%)患者接受手术。
- 意向性分析中65.1%患者达到R0切除,手术相关不良并发症实验组2例(11.8%)vs对照组1例(7.7%)。
核心结论
- 作者认为,不可切除直肠癌短程术前放疗后MRI模拟引导加量的毒性可接受,临床试验将按计划继续。
研究设计与样本
- 随机II期试验的中期分析,入组经盆腔MRI评估为临床T3-4期或区域淋巴结阳性伴直肠系膜筋膜阳性或T4b的直肠癌患者。
- 患者随机分为SCPRT加量组(25 Gy分5次+肿瘤区4 Gy,后4周期化疗)或术前放化疗组(50 Gy分25次同步化疗),随后行全直肠系膜切除术。
- 主要终点为R0切除率;42例完成既定治疗时进行中期分析。
主要发现
- 2018年10月至2019年11月共入组43例,42例纳入中期分析。
- 术前治疗期间≥3级毒性实验组10/21(47.6%)vs对照组4/21(19.0%)。
- 实验组17例(81.0%)与对照组13例(61.9%)接受手术。
- 意向性分析中65.1%患者达到R0切除。
- 手术相关不良并发症实验组2例(11.8%)vs对照组1例(7.7%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The safety of an MRI simulation-guided boost after short-course preoperative radiotherapy (SCPRT) for unresectable rectal cancer is assessed with a planned interim analysis. METHODS AND MATERIALS: Patients diagnosed with clinical stage T3-4 or regional lymph node-positive disease with positive mesorectal fascia or T4b disease evaluated by pelvic MRI were randomly assigned to the SCPRT-boost group (25 Gy in 5 fractions plus 4 Gy delivered to the gross tumor volume, followed by four cycles of chemotherapy) or preoperative chemoradiotherapy group (50 Gy in 25 fractions with concurrent chemotherapy). Then, patients received total mesorectal excision surgery after preoperative treatment. The primary endpoint was the R0 resection rate. The interim analysis was performed when 42 patients completed their assigned treatments. RESULTS: From October 2018 to November 2019, a total of 43 patients were enrolled, and 42 patients were included in the interim analysis. During preoperative therapy, grade 3 or above toxicities were observed in 10/21 (47.6%) patients in the experimental group, and 4/21 (19.0%) patients in the control group. A total of 17 (81.0%) and 13 (61.9%) patients in the experimental group and control group underwent surgery, respectively. Overall, 65.1% of the patients achieved R0 resection in the intention-to-treat analysis. Surgery-related adverse complications were observed in 2 patients (11.8%) in the experimental group and 1 patient (7.7%) in the control group. CONCLUSION: Our results show that the toxicity of an MRI simulation-guided boost after SCPRT for unresectable rectal cancer is acceptable. Thus, this clinical trial will be continued as planned.
引用
- Liu WY, Shi JM, Li N, et al. The safety of an MRI simulation-guided boost after short-course preoperative radiotherapy for unresectable rectal cancer (SUNRISE): interim analysis of a randomized phase II trial. Radiat Oncol. 2022. PMID: 36578032. doi:10.1186/s13014-022-02182-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。